KR20220110726A - 트리아졸 항진균 화합물 pc945의 다형체 - Google Patents

트리아졸 항진균 화합물 pc945의 다형체 Download PDF

Info

Publication number
KR20220110726A
KR20220110726A KR1020227012753A KR20227012753A KR20220110726A KR 20220110726 A KR20220110726 A KR 20220110726A KR 1020227012753 A KR1020227012753 A KR 1020227012753A KR 20227012753 A KR20227012753 A KR 20227012753A KR 20220110726 A KR20220110726 A KR 20220110726A
Authority
KR
South Korea
Prior art keywords
compound
polymorphic
pharmaceutical composition
water
mycoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012753A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 존 월리스
제랄드 스틸
수잔 부타
오사마 술레이만
줄리안 노덴
존 미키티욱
제이미 마샬
Original Assignee
풀모사이드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 풀모사이드 리미티드 filed Critical 풀모사이드 리미티드
Publication of KR20220110726A publication Critical patent/KR20220110726A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
KR1020227012753A 2019-12-06 2020-12-04 트리아졸 항진균 화합물 pc945의 다형체 Pending KR20220110726A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1917867.2 2019-12-06
GBGB1917867.2A GB201917867D0 (en) 2019-12-06 2019-12-06 Polymorphs
PCT/GB2020/053107 WO2021111142A1 (en) 2019-12-06 2020-12-04 Polymorphs of triazole antifungal compound pc945

Publications (1)

Publication Number Publication Date
KR20220110726A true KR20220110726A (ko) 2022-08-09

Family

ID=69171938

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012753A Pending KR20220110726A (ko) 2019-12-06 2020-12-04 트리아졸 항진균 화합물 pc945의 다형체

Country Status (26)

Country Link
US (1) US12491182B2 (enExample)
EP (2) EP4069690B1 (enExample)
JP (1) JP2023505227A (enExample)
KR (1) KR20220110726A (enExample)
CN (1) CN114746415B (enExample)
AU (1) AU2020397613A1 (enExample)
BR (1) BR112022006259A2 (enExample)
CA (1) CA3155829A1 (enExample)
CL (1) CL2022001464A1 (enExample)
CO (1) CO2022007808A2 (enExample)
DK (1) DK4069690T3 (enExample)
ES (1) ES3000984T3 (enExample)
FI (1) FI4069690T3 (enExample)
GB (1) GB201917867D0 (enExample)
HR (1) HRP20250042T1 (enExample)
HU (1) HUE069799T2 (enExample)
IL (1) IL293401A (enExample)
LT (1) LT4069690T (enExample)
MX (1) MX2022006654A (enExample)
PL (1) PL4069690T3 (enExample)
PT (1) PT4069690T (enExample)
RS (1) RS66401B1 (enExample)
SA (1) SA522432879B1 (enExample)
SI (1) SI4069690T1 (enExample)
SM (1) SMT202400514T1 (enExample)
WO (1) WO2021111142A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6669751B2 (ja) 2014-12-05 2020-03-18 プルモシデ リミテド 抗真菌化合物
CN117510488B (zh) * 2022-07-28 2025-12-05 博瑞制药(苏州)有限公司 一种硫酸艾沙康唑的制备方法
CN117330660A (zh) * 2023-09-14 2024-01-02 广州医科大学附属第一医院（广州呼吸中心） Uplc-ms/ms联用检测艾沙康唑的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
EP0318214B1 (en) 1987-11-20 1994-12-14 Schering Corporation Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
HU225062B1 (en) 1993-12-21 2006-05-29 Schering Corp Tetrahydrofuran derivatives with antifungal- effect, pharmaceutical compositions containing them and process for their preparation
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
CZ59497A3 (en) 1995-06-02 1997-08-13 Schering Corp Tetrahydrofuran derivative and pharmaceutical composition containing thereof
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
EP1372394A1 (en) 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
US9346791B2 (en) 2011-09-07 2016-05-24 The Johns Hopkins University Itraconazole analogs and use thereof
JP6669751B2 (ja) 2014-12-05 2020-03-18 プルモシデ リミテド 抗真菌化合物

Also Published As

Publication number Publication date
EP4069690B1 (en) 2024-11-13
PL4069690T3 (pl) 2025-03-10
DK4069690T3 (da) 2025-01-20
ES3000984T3 (es) 2025-03-04
FI4069690T3 (fi) 2025-01-21
US20230028714A1 (en) 2023-01-26
EP4069690A1 (en) 2022-10-12
CO2022007808A2 (es) 2022-06-30
MX2022006654A (es) 2022-09-07
CN114746415A (zh) 2022-07-12
JP2023505227A (ja) 2023-02-08
SA522432879B1 (ar) 2025-01-26
CA3155829A1 (en) 2021-06-10
CN114746415B (zh) 2025-04-11
US12491182B2 (en) 2025-12-09
PT4069690T (pt) 2024-12-13
CL2022001464A1 (es) 2023-03-24
SI4069690T1 (sl) 2025-03-31
LT4069690T (lt) 2025-01-10
IL293401A (en) 2022-07-01
BR112022006259A2 (pt) 2022-06-21
EP4509179A2 (en) 2025-02-19
GB201917867D0 (en) 2020-01-22
HRP20250042T1 (hr) 2025-03-14
HUE069799T2 (hu) 2025-04-28
AU2020397613A1 (en) 2022-06-02
WO2021111142A1 (en) 2021-06-10
SMT202400514T1 (it) 2025-01-14
EP4509179A3 (en) 2025-02-26
RS66401B1 (sr) 2025-02-28

Similar Documents

Publication Publication Date Title
KR20220110726A (ko) 트리아졸 항진균 화합물 pc945의 다형체
EP3490978B1 (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
CN112375073A (zh) 抗真菌的化合物
US10513511B2 (en) Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
HK40124005A (en) Polymorphs
HK40082086A (en) Polymorphs of triazole antifungal compound pc945
HK40082086B (en) Polymorphs of triazole antifungal compound pc945
EA048470B1 (ru) Полиморфы триазольного противогрибкового соединения pc945
RU2843949C2 (ru) Твердые формы n-трет-бутил-4[[2-(5-хлор-2-гидроксифенил)ацетил]амино]пиридин-2-карбоксамида
JP7627683B2 (ja) Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態
HK40009059A (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
HK40009059B (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
WO2025223528A1 (zh) 嘧啶并[6,1-a]异喹啉-4-酮衍生物
HK40046347A (en) Antimycotic compound
HK1252779B (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1-yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof
BR112017020807B1 (pt) Composto 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4- difluorofenil)tetra-hidrofuran-3-il)metóxi)-3-metilfenil)piperazin-1-il)-n-(2- hidroxiciclo-hexil) benzamida antifúngica, seu processo de preparação, e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902